The Claim

Survodutide, a dual glucagon receptor/GLP-1 receptor agonist, reduces HbA1c in a dose-dependent manner in adults with type 2 diabetes on metformin, with maximal efficacy at 1.8 mg once weekly producing a mean reduction of approximately 1.7% over 16 weeks, and its effect at 0.9 mg (mean reduction 1.46%) is similar to that of semaglutide 1.0 mg once weekly (mean reduction 1.47%).

Source: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
87score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with type 2 diabetes who take metformin, the drug survodutide lowers blood sugar levels (HbA1c) more as the dose increases. The highest dose tested, 1.8 mg once weekly, reduced HbA1c by about 1.7% over 16 weeks. At a lower dose of 0.9 mg, survodutide reduces HbA1c by about 1.46%, which is similar to the reduction from a standard dose of another diabetes drug, semaglutide (1.0 mg).

See the scientific wording

The dual glucagon receptor/GLP-1 receptor agonist survodutide reduces HbA1c in a dose-dependent manner in adults with type 2 diabetes on metformin, with maximal efficacy at 1.8 mg once weekly, producing a mean reduction of approximately 1.7% (18.7 mmol/mol) over 16 weeks. This effect is similar to that of semaglutide 1.0 mg once weekly at lower doses (0.9 mg survodutide: -1.46% vs -1.47%).

Why this might work

Survodutide works by turning on two body switches. One switch tells the pancreas to release more insulin and the stomach to slow digestion, lowering blood sugar. The other switch makes the liver burn more energy and fat, helping to improve blood sugar control.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

    The clinical trial showed that survodutide lowers blood sugar (HbA1c) in a dose-dependent way; the best once-weekly dose (1.8 mg) cut HbA1c by about 1.7% after 16 weeks, and a lower dose (0.9 mg) worked just as well as the existing drug semaglutide.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.